Pieris Pharmaceuticals, Inc. Share Price

Equities

PIRS

US7207952026

Biotechnology & Medical Research

Delayed Nasdaq 20:35:07 18/07/2024 BST 5-day change 1st Jan Change
7.65 USD +3.38% Intraday chart for Pieris Pharmaceuticals, Inc. +17.15% -47.46%
Sales 2022 25.9M 2B Sales 2023 42.81M 3.31B Capitalization 17.99M 1.39B
Net income 2022 -33M -2.55B Net income 2023 -24M -1.85B EV / Sales 2022 1.21 x
Net cash position 2022 46.07M 3.56B Net cash position 2023 26.37M 2.04B EV / Sales 2023 -0.2 x
P/E ratio 2022
-2.32 x
P/E ratio 2023
-0.67 x
Employees 48
Yield 2022 *
-
Yield 2023
-
Free-Float 93.03%
More Fundamentals * Estimated data
Dynamic Chart
1 day+3.38%
1 week+17.15%
Current month-22.02%
1 month-17.16%
3 months-38.41%
6 months-42.57%
Current year-47.46%
More quotes
1 week
6.20
Extreme 6.2
7.97
1 month
6.20
Extreme 6.2
10.30
Current year
6.20
Extreme 6.2
22.32
1 year
6.20
Extreme 6.2
41.78
3 years
6.20
Extreme 6.2
492.00
5 years
6.20
Extreme 6.2
492.00
10 years
6.20
Extreme 6.2
780.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 48 31/12/09
Director of Finance/CFO 49 30/11/17
Chief Tech/Sci/R&D Officer - 31/12/16
Members of the board TitleAgeSince
Director/Board Member 59 19/09/16
Chairman 69 21/05/17
Director/Board Member 63 16/12/14
More insiders
Date Price Change Volume
18/07/24 7.65 +3.38% 37 358
17/07/24 7.4 -1.59% 29,377
16/07/24 7.52 +1.48% 43,895
15/07/24 7.41 +8.18% 86,754
12/07/24 6.85 +4.90% 76,865

Delayed Quote Nasdaq, July 18, 2024 at 08:35 pm

More quotes
Pieris Pharmaceuticals, Inc. is a biotechnology company, which discovers and develops Anticalin-based drugs to target validated disease pathways. The Company’s clinical pipeline consists of immuno-oncology (IO), bispecific in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Its Anticalin platform technology focuses on low molecular-weight Anticalin proteins that can bind tightly and specifically to a diverse range of targets. The Anticalin technology is modular, which allows it to design multimeric Anticalin based bi- and multi- specific proteins to bind with specificity to two or more targets at the same time. S095012 consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins genetically fused to each arm of the C-terminal heavy chain of the antibody.
More about the company